1. Home
  2. FATE

FATE

Fate Therapeutics Inc.

Logo Fate Therapeutics Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Founded: 2007 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 835.2M IPO Year: 2013
Target Price: $7.00 AVG Volume (30 days): 2.8M
Analyst Decision: Hold Number of Analysts: 14
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.64 EPS Growth: N/A
52 Week Low/High: $1.63 - $8.83 Next Earning Date: 05-01-2024
Revenue: $63,533,000 Revenue Growth: -34.03%
Revenue Growth (this year): -93.26% Revenue Growth (next year): -30.58%

Share on Social Networks: